Duchenne氏肌肉失养症市场规模、份额、成长分析、按类型、按治疗类型、按诊断、按最终用户、按地区 - 行业预测，2025-2032 年

2023年，全球Duchenne氏肌肉失养症市场规模为21亿美元，从2024年的23.4亿美元成长到2032年的56.4亿美元，复合年增长率预计将成长11.6%。

随着研究和开发力度加大，寻找针对这种主要影响男性的罕见遗传疾病的可行治疗方法，全球Duchenne氏肌肉失养症(DMD) 市场预计将会成长。 DMD 的特征是进行进行性肌肉无力，可导致智力低下、呼吸衰竭和心臟併发症等严重併发症。目前的治疗方法，如类固醇药物、干细胞疗法和基因疗法，旨在缓解症状，但尚无治疗方法。肌肉萎缩症协会在这一领域做出了重大贡献，最近资助了 75,000 美元用于治疗 DMD 的研究，超过 150 个医疗机构获得了津贴。对基因编辑、外显子跳跃和干细胞应用等创新治疗的日益关注预计将进一步推动 DMD 治疗市场的发展。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 宏观经济指标
• 价值链分析
• 价格分析
• 技术分析
• 监管分析
• 专利分析
• 案例研究

Duchenne氏肌肉失养症市场规模：依类型

• 市场概况
• Duchenne氏肌肉失养症(DMD) 1 型
• Duchenne氏肌肉失养症(DMD) 2 型
• 其他的

按治疗类型分類的Duchenne氏肌肉失养症市场规模

• 市场概况
• 基因治疗
• 类固醇
• 外显子跳跃
• 抗发炎药
• 酵素替代疗法
• 其他的

Duchenne氏肌肉失养症市场规模：依诊断分类

• 市场概况
• 基因检测
• 肌肉切片检查
• 肌电图（EMG）
• 影像技术（MRICT扫描）
• 血液检查（CPK值等）

Duchenne氏肌肉失养症市场规模：依最终用户划分

• 市场概况
• 医院
• 专科诊所
• 居家护理
• 诊断实验室

依给药途径分類的Duchenne氏肌肉失养症市场规模

• 市场概况
• 口服
• 可注射的
• 话题

Duchenne氏肌肉失养症市场规模：按分销管道

• 市场概况
• 医院药房
• 零售药房
• 网路药房
• 其他的

Duchenne氏肌肉失养症市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• Pfizer Inc.（US）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Mylan NV（US）
• Fresenius Kabi AG（Germany）
• Hikma Pharmaceuticals plc（UK）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Bristol Myers Squibb Company（US）
• GSK plc（UK）
• Bayer AG（Germany）
• Sun Pharmaceutical Industries Ltd.（India）
• Boehringer Ingelheim（Germany）
• Sanofi（France）
• Sarepta Therapeutics, Inc.（US）
• Aurobindo Pharma（India）
• Capricor Therapeutics, Inc.（US）
• Catalyst Pharmaceuticals Inc（US）
• EspeRare Foundation（Switzerland）
• FibroGen, Inc.（US）
• Italfarmaco SpA（Italy）

结论和建议

Global Duchenne Muscular Dystrophy Market size was valued at USD 2.1 billion in 2023 and is poised to grow from USD 2.34 billion in 2024 to USD 5.64 billion by 2032, growing at a CAGR of 11.6% during the forecast period (2025-2032).

The global Duchenne muscular dystrophy (DMD) market is poised for growth as research and development efforts intensify to discover viable treatments for this rare hereditary condition, predominantly affecting males. DMD is characterized by progressive muscle weakness and can lead to serious complications such as mental retardation, respiratory failure, and heart complications. Current management approaches, including steroid medications, stem cell therapy, and gene therapy, aim to alleviate symptoms, although no cure exists. The Muscular Dystrophy Association has contributed significantly to this sector, recently funding $75,000 towards research for DMD treatments, with over 150 healthcare institutions receiving grants. Increased focus on innovative therapies such as gene editing, exon skipping, and stem cell applications is expected to further propel the DMD treatment market forward.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Duchenne Muscular Dystrophy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Duchenne Muscular Dystrophy Market Segmental Analysis

Global Duchenne Muscular Dystrophy Market is segmented by Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Duchenne Muscular Dystrophy (DMD) Type 1, Duchenne Muscular Dystrophy (DMD) Type 2 and Others. Based on Treatment Type, the market is segmented into Gene Therapy, Steroids, Exon Skipping, Anti-inflammatory Drugs, Enzyme Replacement Therapy and Others. Based on Diagnosis, the market is segmented into Genetic Testing, Muscle Biopsy, Electromyography (EMG), Imaging Techniques (MRI, CT scan) and Blood Tests (CPK Levels, etc.). Based on End-User, the market is segmented into Hospitals, Specialty Clinics, Home Care and Diagnostic Laboratories. Based on Route of Administration, the market is segmented into Oral, Injectable and Topical. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Duchenne Muscular Dystrophy Market

The global Duchenne Muscular Dystrophy (DMD) market is experiencing significant growth driven by the increasing prevalence of the disorder. Key factors propelling this market include heightened awareness initiatives regarding DMD, the emergence of mutation-specific treatments, and a growing pipeline of therapeutic options. Breakthroughs such as Exondys51 and Translarna, along with corticosteroid-based anti-inflammatory therapies, further contribute to this expansion. Additionally, factors such as rising healthcare costs in developed nations and improved medical reimbursement options enhance market accessibility. The persistent unmet need for effective DMD treatments offers considerable opportunities for market players, prompting numerous companies to initiate clinical trials for innovative therapies.

Restraints in the Global Duchenne Muscular Dystrophy Market

The global Duchenne muscular dystrophy (DMD) market is expected to face significant obstacles, primarily stemming from challenges related to late diagnosis and reduced patient engagement due to prognosis uncertainties. Tracking the effectiveness of DMD treatments is complicated by the requirement for various outcome measures at different disease stages, many of which lack both sensitivity and objectivity. For instance, the widely utilized six-minute walk test can only be administered to ambulant DMD patients aged five and above, necessitating extensive cohorts and time to ascertain meaningful benefits. Moreover, the absence of appropriate outcome measures often leads to the exclusion of very young children and non-ambulant patients from clinical trials, further hindering market growth for DMD treatments.

Market Trends of the Global Duchenne Muscular Dystrophy Market

The global Duchenne muscular dystrophy (DMD) market is witnessing a significant upward trend, propelled by the emergence of innovative pharmaceuticals and disease-modifying therapies. This growth is further bolstered by substantial investments from various pharmaceutical companies dedicated to DMD research, alongside effective collaborations with patient advocacy groups that play a crucial role in fostering regulatory approval processes. As awareness and understanding of DMD enhance, the market is expected to expand, with an increased focus on personalized treatments and gene therapy advancements. This dynamic landscape indicates a promising future for stakeholders involved in DMD care and management, as they strive to address unmet medical needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Duchenne Muscular Dystrophy Market Size by Type & CAGR (2025-2032)

• Market Overview
• Duchenne Muscular Dystrophy (DMD) Type 1
• Duchenne Muscular Dystrophy (DMD) Type 2
• Others

Global Duchenne Muscular Dystrophy Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Gene Therapy
• Steroids
• Exon Skipping
• Anti-inflammatory Drugs
• Enzyme Replacement Therapy
• Others

Global Duchenne Muscular Dystrophy Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Genetic Testing
• Muscle Biopsy
• Electromyography (EMG)
• Imaging Techniques (MRI, CT scan)
• Blood Tests (CPK Levels, etc.)

Global Duchenne Muscular Dystrophy Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Home Care
• Diagnostic Laboratories

Global Duchenne Muscular Dystrophy Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• Topical

Global Duchenne Muscular Dystrophy Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Duchenne Muscular Dystrophy Market Size & CAGR (2025-2032)

• North America (Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment Type, Diagnosis, End-User, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sarepta Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Capricor Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalyst Pharmaceuticals Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EspeRare Foundation (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FibroGen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Italfarmaco S.p.A (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations